Koelle DM, Corey L, Burke RL, Eisenberg RJ, Cohen GH, Pichyangkura R et al.Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 68:2803-2810

Department of Medicine, University of Washington, Seattle 98195.
Journal of Virology (Impact Factor: 4.44). 06/1994; 68(5):2803-10.
Source: PubMed


Lesions resulting from recurrent genital herpes simplex virus (HSV) infection are characterized by infiltration of CD4+ lymphocytes. We have investigated the antigenic specificity of 47 HSV-specific CD4+ T-cell clones recovered from the HSV-2 buttock and thigh lesions of five patients. Clones with proliferative responses to recombinant truncated glycoprotein B (gB) or gD of HSV-2 or purified natural gC of HSV-2 comprised a minority of the total number of HSV-specific clones isolated from lesions. The gC2- and gD2-specific CD4+ clones had cytotoxic activity. The approximate locations of the HSV-2 genes encoding HSV-2 type-specific CD4+ antigens have been determined by using HSV-1 x HSV-2 intertypic recombinant virus and include the approximate map regions 0.30 to 0.46, 0.59 to 0.67, 0.67 to 0.73, and 0.82 to 1.0 units. The antigenic specificity of an HLA DQ2-restricted, HSV-2 type-specific T-cell clone was mapped to amino acids 425 to 444 of VP16 of HSV-2 by sequential use of an intertypic recombinant virus containing VP16 of HSV-2 in an HSV-1 background, recombinant VP16 fusion proteins, and synthetic peptides. Each of the remaining four patients also yielded at least one type-specific T-cell clone reactive with an HSV-2 epitope mapping to approximately 0.67 to 0.73 map units. The antigenic specificities of lesion-derived CD4+ T-cell clones are quite diverse and include at least 10 epitopes. Human T-cell clones reactive with gC and VP16 are reported here for the first time.

Download full-text


Available from: David M Koelle,

Click to see the full-text of:

Article: Koelle DM, Corey L, Burke RL, Eisenberg RJ, Cohen GH, Pichyangkura R et al.Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 68:2803-2810

0 B

See full-text
  • Source
    • "These vaginal mucosal memory CD4 T cells in the FRT are sufficient for protective responses to HSV (44) even in the absence of CD8 T cells. In humans, CD4 T cells specific for multiple viral epitopes localize to the uterine cervix (42, 43, 60) and this resident population is thought to limit the severity of recurrent HSV infections (43). As is the case with HSV-2, pre-existing CD4 TRM cells in the RT may be important for conferring protection against other infections of the urogenital tract such as N. gonorrhoeae, Chlamydia muridarum, and Candida infections (61–64). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tissue-resident memory T cells (TRM) comprise a newly defined subset, which comprises a major component of lymphocyte populations in diverse peripheral tissue sites, including mucosal tissues, barrier surfaces, and in other non-lymphoid and lymphoid sites in humans and mice. Many studies have focused on the role of CD8 TRM in protection; however, there is now accumulating evidence that CD4 TRM predominate in tissue sites, and are integral for in situ protective immunity, particularly in mucosal sites. New evidence suggests that mucosal CD4 TRM populations differentiate at tissue sites following the recruitment of effector T cells by local inflammation or infection. The resulting TRM populations are enriched in T-cell specificities associated with the inducing pathogen/antigen. This compartmentalization of memory T cells at specific tissue sites may provide an optimal design for future vaccination strategies. In addition, emerging evidence suggests that CD4 TRM may also play a role in immunoregulation and immunopathology, and therefore, targeting TRM may be a viable therapeutic approach to treat inflammatory diseases in mucosal sites. This review will summarize our current understanding of CD4 TRM in diverse tissues, with an emphasis on their role in protective immunity and the mechanisms by which these populations are established and maintained in diverse mucosal sites.
    Frontiers in Immunology 07/2014; 5:331. DOI:10.3389/fimmu.2014.00331
  • Source
    • "Clinical and experimental evidence suggests that various microbes are able to affect the HIV-1 life cycle by changing the systemic and/or local environment [69]–[75] or by interacting with HIV-1 directly [76], [77]. For example, microbial infection may lead to the modulation of cell activation (HSV-2) [78], to changes in receptor expression (HSV-2, HHV-7, GBV-C) [13], [14], [79]–[81], and to the release of chemokines (HHV-6, GBV-C) [11], [13] that affect HIV cell entry and replication. Moreover, R5 and X4 HIV-1 may be affected in different ways [82], [83], raising the possibility that coinfecting microbes may play an important role in the switch from R5 to X4 dominance [11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The first line of a host's response to various pathogens is triggered by their engagement of cellular pattern recognition receptors (PRRs). Binding of microbial ligands to these receptors leads to the induction of a variety of cellular factors that alter intracellular and extracellular environment and interfere directly or indirectly with the life cycle of the triggering pathogen. Such changes may also affect any coinfecting microbe. Using ligands to Toll-like receptors (TLRs) 5 and 9, we examined their effect on human immunodeficiency virus (HIV)-1 replication in lymphoid tissue ex vivo. We found marked differences in the outcomes of such treatment. While flagellin (TLR5 agonist) treatment enhanced replication of CC chemokine receptor 5 (CCR 5)-tropic and CXC chemokine receptor 4 (CXCR4)-tropic HIV-1, treatment with oligodeoxynucleotide (ODN) M362 (TLR9 agonist) suppressed both viral variants. The differential effects of these TLR ligands on HIV-1 replication correlated with changes in production of CC chemokines CCL3, CCL4, CCL5, and of CXC chemokines CXCL10, and CXCL12 in the ligand-treated HIV-1-infected tissues. The nature and/or magnitude of these changes were dependent on the ligand as well as on the HIV-1 viral strain. Moreover, the tested ligands differed in their ability to induce cellular activation as evaluated by the expression of the cluster of differentiation markers (CD) 25, CD38, CD39, CD69, CD154, and human leukocyte antigen D related (HLA)-DR as well as of a cell proliferation marker, Ki67, and of CCR5. No significant effect of the ligand treatment was observed on apoptosis and cell death/loss in the treated lymphoid tissue ex vivo. Our results suggest that binding of microbial ligands to TLRs is one of the mechanisms that mediate interactions between coinfected microbes and HIV-1 in human tissues. Thus, the engagement of appropriate TLRs by microbial molecules or their mimetic might become a new strategy for HIV therapy or prevention.
    PLoS ONE 09/2010; 5(9). DOI:10.1371/journal.pone.0012831 · 3.23 Impact Factor
  • Source
    • "APC were γ-irradiated (3,300 rads). Assays used 200 μl T-cell medium (Koelle et al., 1994b) in 96-well U-bottom plates with addition of 3 H thymidine (0.5 μCi/well) at 72 hours and harvesting 7–20 hours later. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The CD4 T-cell response to vaccinia promotes antibody and long-term CD8 responses. HLA class II molecules present microbial epitopes to CD4 T-cells. In humans, at least 3 loci encode cell-surface peptide-binding HLA class II heterodimers. Using intracellular cytokine cytometry (ICC) assays, we determined that HLA DR had the strongest contribution to vaccinia antigen presentation. Among panels of vaccinia-restricted T-cell clones, most were DR-restricted but rare DQ-restricted clones were also recovered. Vaccinia has over 200 open reading frames (ORFs), providing a significant bottleneck to assigning fine specificity. To overcome this, we expressed each predicted vaccinia ORF using in vitro transcription and translation. Array-based pool proteins were used to rapidly assign fine specificity to each DQ-restricted clone and to a sample of HLA DR-restricted clones. Reactivity was confirmed using synthetic peptides for selected CD4 T-cell clones. This method should be broadly applicable to the study of large-genome, sequenced pathogens, and could also be used to investigate T-cell responses to cDNAs expressed in neoplastic and autoimmune disorders in which CD4 responses might be adaptive or harmful.
    Journal of immunological methods 07/2009; 347(1-2):36-45. DOI:10.1016/j.jim.2009.05.011 · 1.82 Impact Factor
Show more